February 22, 2024

Anti-Rheumatics Market Growth Driven by Novel Biologic Launches

The global anti-rheumatics market is experiencing a significant transformation, with biologic disease-modifying anti-rheumatic drugs (DMARDs) surpassing conventional therapies in terms of revenue. Rheumatoid arthritis (RA), an autoimmune condition affecting millions worldwide, has seen a remarkable shift towards more targeted and potent biologic treatments. This shift is driven by the superior efficacy of biologics in treating RA, compared to traditional DMARDs.

Biologics Take the Lead: Biologics, including Tumor Necrosis Factor (TNF) inhibitors, Interleukin-1 inhibitors, Interleukin-6 inhibitors, T cell inhibitors, and B cell inhibitors, have emerged as the frontrunners in the treatment of RA. Notably, the top five biologics now contribute to over half of the global anti-rheumatics market.

Traditional vs. Biologic DMARDs: Traditional DMARDs, such as Sulfasalazine, Hydroxychloroquine, Leflunomide, Methotrexate, and Azathioprine, have long been the cornerstone of RA treatment. However, the effectiveness and precision of biologics have set a new standard in combating this chronic condition.

Growing RA Prevalence: Rheumatoid arthritis predominantly strikes individuals between the ages of 20 and 40, causing chronic pain and deformity. It is more common in women, particularly in developed countries, where nearly 50% of RA patients are unable to maintain full-time employment within a decade of onset. The market is witnessing continued growth, driven by a rising prevalence of RA and the introduction of novel therapeutics.

Biosimilar Challenge: Despite the growth trajectory, the anti-rheumatics market faces challenges from biosimilars eroding the sales of existing blockbuster drugs. Patent expirations for market-leading drugs like Enbrel, Humira, and Remicade have paved the way for biosimilars, impacting market growth. Nevertheless, novel entrants like Amjevita, Rinvoq, and Filgotinib are expected to invigorate the market.

See also  Tapioca Flour Market Flourishes as Health-conscious Consumers Seek Gluten-free Options

Impact of COVID-19: The COVID-19 pandemic has led to a reduction in the number of new RA patients seeking immunosuppressive therapies. Concerns about compromising the immune system have contributed to a decline in the demand for immunosuppressive treatments for conditions like RA during the pandemic.

North America Leads the Way: North America, particularly the United States, boasts a high prevalence of RA, with significant mortality hazards associated with the condition. Europe also reports a substantial prevalence of RA, making it a key market for anti-rheumatics.

Competitive Landscape: The anti-rheumatics market has become increasingly crowded, featuring multiple therapies representing various drug classes, including TNF-α inhibitors, non-TNF-α biologics, and oral JAK inhibitors. The competition for a larger revenue share in this market is intensifying with recent approvals for additional JAK inhibitors and the emergence of biosimilars.

Key Market Players: Key players in the anti-rheumatics space include AbbVie Inc., Amgen Inc., Gilead Sciences Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Celgene Corporation, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and UCB S.A.

The anti-rheumatics market is poised for growth, driven by the increasing prevalence of RA, novel therapeutic launches, and advancements in biologic treatments. As the market continues to evolve, it presents both challenges and opportunities for pharmaceutical companies aiming to address the needs of patients with rheumatoid arthritis.

Global Industry Analysis (2018 – 2021) – Growth Trends and Market Forecast (2022 – 2029) https://www.fairfieldmarketresearch.com/report/anti-rheumatics-market

Visit Our Blogs:



About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

See also  Liquid Packaging Market Adapts to Shifting Trends with Focus on Flexibility and Sustainability


Fairfield Market Research

London, UK

UK +44 (0)20 30025888

USA (Toll-free) +1 (844) 3829746



LinkedIn | Twitter

This press release first seen on Brilad